Vall d’Hebron Invests 50 Million in Projects Against Stroke and Nuclear Medicine

Vall d’Hebron is committed to innovative public purchasing. The hospital center invests €50 million in two innovation projects for its campus, specializing in research against stroke and support for nuclear medicine, according to Albert Salazar, manager of Vall d’Hebron.

Both projects are part of innovative public purchasing, which seeks to enhance health results. The first initiative is the implementation of One Step Stroke, with which ischemic and hemorrhagic stroke patient care will be concentrated in a single space in the hospital. The investment in this project amounts to €25 million, according to Salazar.

The space of the hospital center for stroke is designed to incorporate a solution that combines biplane equipment to perform mechanical thrombectomy, a procedure to remove thrombi that cause disease, with technology to perform CT scans before, during, and after thrombectomy. and assess the patient’s brain activity.

Read more on the subject and find the latest business headlines of the day with the Born2Invest mobile app.

Vall d’Hebron estimates that more than 500 patients can benefit from the new program against stroke

The patient who presents symptoms of stroke will go directly to the One Step Stroke room, without having to go through the traditional emergency circuit, according to the manager of the Catalan hospital.

Vall d’Hebron treats around 1,800 patients with ischemic and hemorrhagic stroke each year, and it is estimated that approximately 560 patients will benefit from One Step Stroke.

The other innovative public purchase project is Ciclocat, whose investment amounts to €25 million. This involves the incorporation of the first cyclotron in a public hospital in Catalonia, which will reinforce the nuclear medicine area of ​​the Barcelona health complex. With the building underway, the novelty is that the hospital will now begin to tender all the necessary equipment, according to Salazar. This commitment will allow the center to accelerate radiopharmacy and advance against neurological or oncological diseases.

Previously, the hospital had already carried out innovative public procurement projects such as the creation of an advanced clinical center, the digitization of pathological samples or rehabilitation in a day hospital. The manager of Vall d’Hebron explains that between the initiatives already undertaken and those to which they aspire, in terms of innovative public purchasing, the final amount amounts to more than 150 million euros.

Vall d’Hebron is one of the main public hospitals in Spain. The center received 1.1 million outpatient visits (115,422 more than in 2020), more than 180,600 emergencies, and 34,819 major surgical interventions in 2021, according to the latest results provided by the center.

__

(Featured image by geralt via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.